Ovoca Bio (LSE:OVB) Notes Receivable : £0.00 Mil (As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Ovoca Bio Notes Receivable?

Ovoca Bio's Notes Receivable for the quarter that ended in Jun. 2024 was £0.00 Mil.

Ovoca Bio Notes Receivable Historical Data

The historical data trend for Ovoca Bio's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Notes Receivable Chart

Ovoca Bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Get a 7-Day Free Trial

Ovoca Bio Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Ovoca Bio Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Ovoca Bio Notes Receivable Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (LSE:OVB) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

OVXA:Ireland OVB.GB:UK OVXA:Germany

Address

17 Pembroke Street Upper, Dublin, IRL, D02 AT22

Website

https://www.ovocabio.com

Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.